EUVIMEDEUVIMED entdecken
Open Access · CC BY-NC 4.0

Effects of imeglimin on experimental diabetic neuropathy in streptozotocin‐induced diabetic rats

Wataru Nihei iD, Ayako Kato, Takuma Sato, Masahiro Yamaguchi, Tatsuhito Himeno, Nobuhisa Nakamura iD, Kazunori Sango iD, Keiko Naruse iD, Jiro Nakamura, Hideki Kamiya iD, Koichi Kato

Journal of Diabetes Investigation · 2026

DOI: 10.1111/jdi.70303 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Journal of Diabetes Investigation, 2026. Verfasst von Wataru Nihei und 10 weiteren Autor:innen. Beteiligte Einrichtung: Laboratory of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Aichi, Japan. Hauptthemen laut MEDLINE: Diabetes Mellitus, Experimental, Diabetic Neuropathies, Triazines. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 50 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: Japan Society for the Promotion of Science.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims/Introduction As a common chronic complication, diabetic neuropathy affects a substantial number of individuals with diabetes mellitus, with limited therapeutic options addressing the underlying pathogenesis. The glucose‐lowering action of imeglimin is mediated through improved insulin sensitivity in peripheral organs, including the skeletal muscle and liver, along with augmented insulin release from β‐cells. Imeglimin exerts its effects in part by modulating mitochondrial complex I, leading to the reduced production of reactive oxygen species and protection against metabolic stress. Despite these beneficial effects, the effect of imeglimin on diabetic neuropathy remains unclear. In this study, we evaluated whether imeglimin ameliorated peripheral nerve dysfunction in streptozotocin (STZ)‐induced diabetic rats. Materials and Methods The rats received imeglimin (200 mg/kg twice daily) or vehicle for 4 weeks, and the sensory nerve conduction velocity (SNCV), motor nerve conduction velocity (MNCV), sciatic nerve blood flow (SNBF), and intraepidermal nerve fiber density (IENFD) were assessed. Neurite outgrowth was examined in ND7/23 cells derived from the dorsal root ganglion.

Results

Imeglimin treatment significantly improved SNCV, SNBF, and IENFD without affecting blood glucose levels, indicating neuroprotective effects, independent of glycemic control. Furthermore, imeglimin enhanced neurite outgrowth in ND7/23 cells, demonstrating its direct neurotrophic effect. These findings indicate that imeglimin protects against diabetic neuropathy by enhancing nerve blood flow and promoting neurite growth independent of the systemic control of glycemia.

Conclusions

This study provides supporting evidence for the potential therapeutic application of imeglimin in diabetic neuropathy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Diabetes Mellitus, ExperimentalDiabetic NeuropathiesTriazinesAnimalsMaleRatsBlood GlucoseGanglia, SpinalNerve Conduction StudiesNeural ConductionRats, Sprague-DawleySciatic NerveStreptozocin

Stichwörter der Autor:innen

diabetes mellitusdiabetic neuropathyimeglimin

Substanzen

Blood GlucoseimegliminStreptozocinTriazines

Autor:innen und Institutionen

  • Laboratory of Medicine, Aichi Gakuin University School of Pharmacy, Nagoya, Aichi, Japan.
  • Division of Diabetes, Department of Internal Medicine, Aichi Medical University School of Medicine, Nagakute, Aichi, Japan.
  • Department of Internal Medicine, School of Dentistry, Aichi Gakuin University, Nagoya, Aichi, Japan.
  • Diabetic Neuropathy Project, Department of Diseases and Infection, Tokyo Metropolitan Institute of Medical Science, Tokyo, Japan.
  • TDE Healthcare Corporation TOSAKI Meito Clinic for Diabetes and Endocrinology, Nagoya, Aichi, Japan.

ORCID-Profile: Wataru Nihei, Nobuhisa Nakamura, Kazunori Sango, Keiko Naruse, Hideki Kamiya

Förderung

  • Japan Society for the Promotion of Science

Zitieren

APA

Nihei, W., Kato, A., Sato, T., Yamaguchi, M., Himeno, T., Nakamura, N., Sango, K., Naruse, K., Nakamura, J., Kamiya, H., & Kato, K. (2026). Effects of imeglimin on experimental diabetic neuropathy in streptozotocin‐induced diabetic rats. Journal of Diabetes Investigation. https://doi.org/10.1111/jdi.70303

Vancouver

Nihei W, Kato A, Sato T, Yamaguchi M, Himeno T, Nakamura N, et al. Effects of imeglimin on experimental diabetic neuropathy in streptozotocin‐induced diabetic rats. Journal of Diabetes Investigation. 2026. doi:10.1111/jdi.70303

BibTeX
@article{Nihei2026,
  author = {Nihei, Wataru and Kato, Ayako and Sato, Takuma and Yamaguchi, Masahiro and Himeno, Tatsuhito and Nakamura, Nobuhisa and Sango, Kazunori and Naruse, Keiko and Nakamura, Jiro and Kamiya, Hideki and Kato, Koichi},
  title = {Effects of imeglimin on experimental diabetic neuropathy in streptozotocin‐induced diabetic rats},
  journal = {Journal of Diabetes Investigation},
  year = {2026},
  doi = {10.1111/jdi.70303}
}
Kostenlos starten →